Who owns GLUE?
Institutional ownership of Monte Rosa Therapeutics Inc. from Form 13F, Q2 2026
193 institutional managers reported holding Monte Rosa Therapeutics Inc. (GLUE) in Form 13F filings for Q2 2026, with 93,321,372 shares worth $2.3B. The largest reported holder was Price T Rowe Associates Inc. Managers that filed both quarters added a net 6,011,062 shares (+7.0%). 27 opened new positions and 23 sold out.
- Funds holding
- 193
- Value held
- $2.3B
- New / sold out
- 27 / 23
- Net shares, same filers
- +7.0%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of GLUE
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Price T Rowe Associates Inc | $214M | 9.5% | 8,861,171 | Added |
| NEA Management Company, LLC | $186M | 8.2% | 7,692,298 | Unchanged |
| BlackRock, Inc. | $166M | 7.3% | 6,843,087 | Added |
| TCG Crossover Management, LLC | $112M | 5.0% | 4,622,151 | Unchanged |
| Vestal Point Capital, LP | $111M | 4.9% | 4,600,000 | Added |
| BVF Inc | $108M | 4.8% | 4,460,886 | Unchanged |
| Baker Bros. Advisors LP | $105M | 4.7% | 4,345,736 | Unchanged |
| State Street Corp | $90.3M | 4.0% | 3,731,416 | Added |
| Montanova Capital, LLC | $85.9M | 3.8% | 3,549,539 | Trimmed |
| Vanguard Capital Management LLC | $82.6M | 3.7% | 3,412,927 | Added |
| Versant Venture Management, LLC | $77.0M | 3.4% | 3,180,780 | Unchanged |
| Braidwell LP | $59.3M | 2.6% | 2,451,562 | Trimmed |
| Geode Capital Management, LLC | $45.1M | 2.0% | 1,864,113 | Added |
| American Century Companies Inc | $39.3M | 1.7% | 1,622,846 | Trimmed |
| Marshall Wace, LLP | $38.6M | 1.7% | 1,593,600 | Added |
| Aisling Capital Management LP | $37.6M | 1.7% | 1,555,664 | Unchanged |
| Nantahala Capital Management, LLC | $31.6M | 1.4% | 1,303,986 | Added |
| Bellevue Group AG | $28.8M | 1.3% | 1,190,000 | Trimmed |
| Dimensional Fund Advisors LP | $28.5M | 1.3% | 1,177,488 | Added |
| MPM Bioimpact LLC | $28.1M | 1.2% | 1,161,081 | Trimmed |
| Silverarc Capital Management, LLC | $26.8M | 1.2% | 1,108,295 | Trimmed |
| Jupiter Topco LLC | $26.0M | 1.1% | 1,072,494 | First report |
| Frazier Life Sciences Management, L.P. | $24.2M | 1.1% | 1,000,000 | Unchanged |
| Goldman Sachs Group Inc | $24.2M | 1.1% | 998,253 | Trimmed |
| Woodline Partners LP | $23.3M | 1.0% | 962,884 | Added |
Share of 13F holdings is each fund's shares as a share of the 93,321,372 GLUE shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Price T Rowe Associates Inc Added+$51.8M
- BlackRock, Inc. Added+$29.2M
- Vestal Point Capital, LP Added+$24.1M
- Woodline Partners LP Added+$21.5M
- Opaleye Management Inc. New+$18.0M
- Nantahala Capital Management, LLC Added+$15.8M
- First Trust Advisors LP New+$15.7M
- Boone Capital Management LLC New+$14.9M
- Nextech Invest Ltd. Added+$11.1M
- State Street Corp Added+$9.1M
Biggest sellers in Q2 2026
- American Century Companies Inc Trimmed-$28.7M
- Silverarc Capital Management, LLC Trimmed-$21.6M
- Braidwell LP Trimmed-$18.3M
- Montanova Capital, LLC Trimmed-$16.4M
- Arrowstreet Capital, Limited Partnership Sold out-$10.7M
- Alphabet Inc. Trimmed-$7.5M
- Renaissance Technologies LLC Trimmed-$6.7M
- Cormorant Asset Management, LP Sold out-$6.6M
- Northern Trust Corp Trimmed-$4.2M
- J. Goldman & Co LP Trimmed-$3.8M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $332M and sold $173M; 82 added and 58 trimmed.
Schedule 13D and 13G filings on GLUE
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2025-10-03Dimension Capital I, L.P. SCHEDULE 13G filed by Monte Rosa Therapeutics Inc.Schedule 13G
- 2025-04-16SUVRETTA CAPITAL MANAGEMENT, LLC SCHEDULE 13G filed by Monte Rosa Therapeutics Inc.Schedule 13G
- 2025-02-04BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2025-01-31BIOTECHNOLOGY VALUE FUND L P SCHEDULE 13G filed by Monte Rosa Therapeutics Inc.Schedule 13G
- 2025-01-31VANGUARD GROUP INC SCHEDULE 13G filed by Monte Rosa Therapeutics Inc.Schedule 13G
Questions about GLUE ownership
- Who owns GLUE stock?
- 193 institutional investment managers reported GLUE positions in their Form 13F filings for Q2 2026, holding 93,321,372 shares worth $2.3B in total. Price T Rowe Associates Inc reported the largest position.
- Are funds buying or selling GLUE?
- In Q2 2026, 27 managers opened new GLUE positions, 82 added, 58 trimmed and 23 sold out. Managers that filed in both quarters added a net 6,011,062 shares.
- How current is this GLUE institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to GLUE by CUSIP. Options are left out. GLUE news and filings · GLUE insider trades · Top funds